Arbutus Biopharma Corp
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.1M | $6.2M | $18.1M | $39.0M | $11.0M | $6.9M | $6.0M | $5.9M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $25.2M | $54.0M | $73.7M | $84.4M | $65.5M | $49.3M | $57.6M | $57.9M |
| SG&A Expense | $15.9M | $22.1M | $22.5M | $17.8M | $17.1M | $14.8M | $17.7M | $16.0M |
| Operating Income | $-38.2M | $-76.3M | $-78.1M | $-65.5M | $-73.5M | $-57.8M | $-143.9M | $-89.8M |
| Operating Margin | -271.0% | -1,236.7% | -430.5% | -167.8% | -669.1% | -836.1% | -2,394.0% | -1,510.2% |
| Interest Expense | — | — | $459.0K | $1.7M | $2.9M | $4.0M | $2.1M | $226.0K |
| Pretax Income | — | — | — | — | — | $-63.7M | $-166.4M | $-61.3M |
| Income Tax Expense | $0 | $0 | $0 | $4.4M | $0 | $0 | $-12.7M | $-4.3M |
| Net Income | $-33.5M | $-69.9M | $-72.8M | $-69.5M | $-76.2M | $-63.7M | $-153.7M | $-57.1M |
| Net Margin | -237.9% | -1,133.0% | -401.6% | -178.0% | -693.9% | -922.0% | -2,557.4% | -959.8% |
| EPS (Basic) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | $-2.89 | $-1.21 |
| EPS (Diluted) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | $-2.89 | $-1.21 |
| Shares Outstanding (Basic) | 191.6M | 185.6M | 166.0M | 150.9M | 106.2M | 75.8M | 64.8M | 55.3M |
| Shares Outstanding (Diluted) | 191.6M | 185.6M | 166.0M | 150.9M | 106.2M | 75.8M | 64.8M | 55.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |